Lixin Wan

机构：Moffitt Cancer Center, Jilin Maternity and Child Health Care Hospital, Molecular Oncology (United States), Dalian Maritime University

发表论文 55 篇 · 总被引 289 次 · h-index 9

代表论文

• First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial (2025 · Nature Medicine · 被引 89)
• Association between composite dietary antioxidant index and kidney stone prevalence in adults: data from National Health and Nutrition Examination Survey (NHANES, 2007–2018) (2024 · Frontiers in Nutrition · 被引 18)
• Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial (2024 · Journal of Clinical Oncology · 被引 17)
• A phase 1/2 study of LM-302, an anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate in patients with advanced gastric/gastroesophageal junction cancer. (2024 · Journal of Clinical Oncology · 被引 15)
• Comparison of Helicobacter pylori positive and negative gastric cancer via multi-omics analysis (2023 · mBio · 被引 13)
• Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial (2025 · European Journal of Cancer · 被引 11)